| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
LeoNovus is at the forefront of creating the infrastructure needed for next-generation distributed data centers (DDC) that will enable highly efficient and high-speed cloud and enterprise computing; With the LeoNovus breakthrough and proprietary cloud and infrastructure technology, a virtualized network – or cloud – can be created in a single geo-dispersed DDC from an unlimited number of remotely located, physical data sites comprised of high performance compute and storage end points.
Skience is the award-winning platform for wealth management firms who are looking for a better solution. We power digital transformation.
ICOA, Inc. is a Warwick, RI-based company in the Software & Internet sector.
Novel Staffing is a Dallas, TX-based company in the Software & Internet sector.